Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06712680 | A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes | recruiting | Phase 1 / Phase 2 | 115 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07229586 | A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 |
| Dec 19, 2025 |
| clinicaltrials |
| NCT06825494 | Clinical Studies for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 194 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07003321 | A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 120 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06383884 | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06735144 | Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06703177 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 876 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06925581 | A Trial of HRS-6768 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 84 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06840821 | Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors | recruiting | Phase 1 / Phase 2 | 156 | Mainline Biosciences (Shanghai) Co., LtdOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256782 | A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07241936 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07105215 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07083323 | A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 262 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 862 | DualityBio Inc.INDUSTRY | 4 | Nov 21, 2025 | clinicaltrials |
| NCT04299191 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 28 | Laminar PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06184035 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer(Tumorad) | recruiting | Phase 1 / Phase 2 | 90 | Spago Nanomedical ABINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06500676 | A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 407 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07071103 | Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors(ILDR-02) | recruiting | Phase 2 | 48 | Chuangzhen ChenOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07126665 | A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 116 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07130383 | A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors | recruiting | Phase 2 | 210 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07055594 | A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors(NbTAST-01) | recruiting | Phase 1 / Phase 2 | 76 | Shine-On Biomedical Co., Ltd.INDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05902988 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 200 | Volastra Therapeutics, Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04643418 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 81 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT06249048 | Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 108 | Strand Therapeutics Inc.INDUSTRY | 2 | Oct 29, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT05512208 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib(DURAFAK) | recruiting | Phase 2 | 55 | University of OklahomaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT04954599 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | recruiting | Phase 1 / Phase 2 | 126 | Maastricht University Medical CenterOTHER | 3 | Oct 7, 2025 | clinicaltrials |
| NCT05803018 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies | recruiting | Phase 1 / Phase 2 | 38 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05965856 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05941507 | A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 300 | LigaChem Biosciences, Inc.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06212076 | Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients | recruiting | Phase 1 / Phase 2 | 60 | Nanjing Immunophage Biotech Co., LtdINDUSTRY | 1 | Sep 24, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06520488 | A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 118 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06985355 | A Study of MHB046C Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06868199 | A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 87 | LaNova Medicines LimitedINDUSTRY | 2 | Sep 12, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07170293 | Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors | recruiting | Phase 2 | 15 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06468358 | A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors(TRIGGERCD8) | recruiting | Phase 1 / Phase 2 | 194 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06187402 | A Study of LM-24C5 For Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | LaNova Medicines LimitedINDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07158918 | ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | ABL Bio, Inc.INDUSTRY | 3 | Sep 8, 2025 | clinicaltrials |
| NCT06209580 | AMT-253 in Patients With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 96 | Multitude Therapeutics Inc.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 23, 2025source: clinicaltrials